10 mg lyophilised · single compound
$130.00 CAD
Tesamorelin is a stabilised peptide that signals the body to release growth hormone, used in endocrine research. Studies focus on its effects on the growth-hormone axis and fat metabolism.
For laboratory and research use only - not for human consumption.
Checking the live COA archive for the newest lot documentation.
Use the verification archive to select a peptide name and review all published lot records alphabetically.
View previous lab resultsTesamorelin is a stabilised synthetic analogue (a chemically protected copy) of growth-hormone-releasing hormone (GHRH), the natural signal that tells the pituitary gland to release growth hormone.
Its pivotal human trials (in HIV-associated lipodystrophy - an abnormal redistribution of body fat) showed roughly a 15% reduction in visceral fat (deep abdominal fat) over six months, with improved blood lipids. Research interest centres on the GH/IGF-1 axis and visceral-fat metabolism.
Agonism (activation) of the GHRH receptor, stimulating the body’s own pulsatile growth-hormone release rather than supplying growth hormone directly.
Tesamorelin is the active ingredient of an FDA-approved prescription medicine (Egrifta / Egrifta WR) for HIV-associated lipodystrophy. The material here is an unapproved research compound - it is not that medicine, is not for human use, and is provided for laboratory research only.
A single vial containing 10 mg of Tesamorelin as a lyophilised powder.
